ClearPoint Neuro Inc. (CLPT)
| Market Cap | 370.87M |
| Revenue (ttm) | 12.83M |
| Net Income (ttm) | -6.78M |
| Shares Out | 19.49M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $17.94 |
| Previous Close | $19.26 |
| Change ($) | -1.32 |
| Change (%) | -6.85% |
| Day's Open | 19.51 |
| Day's Range | 17.63 - 19.57 |
| Day's Volume | 629,480 |
| 52-Week Range | 2.90 - 31.29 |
SOLANA BEACH, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...
IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today...
IRVINE, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today...
ClearPoint Neuro, Inc. (CLPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 30.77% and 0.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of ClearPoint Neuro (NASDAQ:CLPT) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 18.18% over the past year to ($0.09), which be...
Company Reports Record Revenues
IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today ...
IRVINE, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today ...
ClearPoint Neuro Inc (NASDAQ: CLPT) has priced its underwritten public offering of 1.85 million shares at $23.50 per share, representing a 9% discount on the last close price of $25.80 on Thursday. Gros...
IRVINE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announ...
IRVINE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announ...
Collaboration will Enable ClearPoint to Develop and Launch the ClearPoint ‘Maestro™' Brain Model by 2022
Partnership Enables ClearPoint Neuro to Compete in New and Complementary Markets Partnership Enables ClearPoint Neuro to Compete in New and Complementary Markets
IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that R. John Fletcher has been appointed Chairman of the Company's Board of Direct...
MRI Interventions, Inc. (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRVINE, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that E...
IRVINE, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported the fir...
IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today ...
Represents Draw of Additional Proceeds from Petrichor Announced in January 2020 Represents Draw of Additional Proceeds from Petrichor Announced in January 2020
IRVINE, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a leader in image-guided stereotactic neurosurgery, announced that its 4,000th neurosurgical procedure using the ...
IRVINE, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a medical device company with a portfolio of products focused on enabling therapies for neurological disorders, t...
About CLPT
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, ... [Read more...]
| Industry Medical Devices | Founded 1998 |
| Stock Exchange NASDAQ | Ticker Symbol CLPT |
Financial Performance
In 2020, CLPT's revenue was $12.83 million, an increase of 14.37% compared to the previous year's $11.22 million. Losses were -$6.78 million, 22.4% more than in 2019.
Analyst Forecasts
According to one analyst, the rating for CLPT stock is "Strong Buy" and the 12-month stock price forecast is 35.00.